Results 121 to 130 of about 4,690 (200)

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study. [PDF]

Life (Basel)
Tosto M, Parisi GF, Presti S, Papale M, Pecora G, Mulè E, Ornato V, Aloisio D, Manti S, Leonardi S.   +9 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [PDF]

Int J Mol Sci
Huang Y, Gonzales Cordova JM, Penrod S, Bendy LL, Cheng PC, Sanders DB, Davis MD, Gaston B, Chmiel JF.   +8 more
europepmc   +1 more source

Modulation of host inflammatory pathways by <i>Pseudomonas aeruginosa</i> extracellular vesicles in cystic fibrosis: impact of pulmonary exacerbation and elexacaftor-tezacaftor-ivacaftor treatment. [PDF]

Front Immunol
Said M, Burrell A, Harmon B, Krohmaly KI, Mazur M, Solomon GM, Hahn A.   +6 more
europepmc   +1 more source

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on <i>Aspergillus fumigatus</i> growth. [PDF]

Microbiol Spectr
Biquand E, Khau S, Fouquenet D, Chouela Mbouwe S, Costes F, Drobecq L, Chesnay A, Desoubeaux G, Briard B.   +8 more
europepmc   +1 more source

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Elexacaftor-Tezacaftor-Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis. [PDF]

Int Forum Allergy Rhinol
Stapleton AL, Kimple A, Goralski JL, Beswick DM, Gupta A, Li DA, Branstetter BF, Nouraie SM, Shaffer AD, Senior B, Zemke AC.   +10 more
europepmc   +1 more source

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. [PDF]

J Clin Endocrinol Metab
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A.   +16 more
europepmc   +1 more source

Predicting Maternal and Fetal Exposures of Elexacaftor-Tezacaftor-Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models. [PDF]

Clin Pharmacol Ther
Hong E, Hebert MF, Fay E, Turner G, Eshaghian P, Trimble A, Chung PS, Rao AP, Beringer PM.   +8 more
europepmc   +1 more source